Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
paroxysmal nocturnal hemoglobinuria
Pharma
AstraZeneca's rare disease add-on therapy Voydeya scores FDA nod
The FDA has approved AstraZeneca's Voydaya, a factor D inhibitor, to treat paroxysmal nocturnal hemoglobinuria patients with extravascular hemolysis.
Kevin Dunleavy
Apr 1, 2024 11:48am
Roche's answer to AstraZeneca PNH drugs nabs China nod
Feb 8, 2024 11:02am
AZ's newest PNH med Voydeya approved in Japan
Jan 19, 2024 11:06am
Novartis gains first FDA approval for touted blood disorder drug
Dec 6, 2023 11:02am
AZ's rare disease rising star Ultomiris snags 3rd FDA nod
Apr 28, 2022 9:15am
Lilly-Innovent, Biogen-Eisai, FDA and more—Fierce Pharma Asia
Feb 11, 2022 6:22am
